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ABSTRACT
Objective To assess whether quality indicators
for treatment of cardiovascular and renal risk
factors are associated with short-term outcomes
in patients with diabetes.
Design A prospective cohort study using linear
regression adjusting for confounders.
Setting The GIANTT database (Groningen
Initiative to Analyse Type 2 Diabetes Treatment)
containing data from primary care medical
records from The Netherlands.
Participants 15 453 patients with type 2
diabetes mellitus diagnosed before 1 January
2008. Mean age 66.5 years, 47.5% men.
Exposure Quality indicators assessing current
treatment (CT) status or treatment intensification
(TI) for patients with diabetes with elevated
cardiovascular or renal risk factors.
Main outcome measures Low-density
lipoprotein cholesterol (LDL-C), systolic blood
pressure (SBP), and albumin:creatinine ratio
(ACR) before and after assessment of treatment
quality.
Results Use of lipid-lowering drugs was
associated with better LDL-C levels (−0.41 mmol/
litre; 95% CI −0.48 to −0.34). Use of blood
pressure-lowering drugs and use of renin–
angiotensin system inhibitors in patients with
elevated risk factor levels was not associated with
better SBP and ACR outcomes, respectively. TI was
also associated with better LDL-C (−0.82 mmol/
litre; CI −0.93 to −0.71) in patients with elevated
LDL-C levels, and with better SBP (−1.26 mm Hg;
CI −2.28 to −0.24) in patients with two elevated
SBP levels. Intensification of albuminuria-lowering
treatment showed a tendency towards better ACR
(−2.47 mmol/mg; CI −5.32 to 0.39) in patients
with elevated ACR levels.
Conclusions Quality indicators of TI were
predictive of better short-term cardiovascular and
renal outcomes, whereas indicators assessing CT
status showed association only with better LDL-C
outcome.
INTRODUCTION
Treatment quality indicators are part of
indicator sets for measuring and improving
quality of care.
1–3 Treatment indicators are
often defined as the percentage of patients
with a certain indication being treated with
medication, such as patients with coronary
heart disease who are treated with a β
blocker or patients with albuminuria
treated with angiotensin-converting
enzyme (ACE) inhibitors.
3 These indicators
measure treatment status in a cross-
sectional manner. For cardiovascular risk
factor control, particularly in patients with
diabetes, clinical action indicators have
been proposed as alternative indicators of
treatment quality.
4–7 Such indicators assess
whether treatment is started or intensified
when indicated, for example, intensifica-
tion of antihypertensive treatment in
patients with elevated blood pressure
levels. They target patients with an inad-
equately controlled condition, and may be
more appropriate for capturing therapeutic
inertia than indicators of treatment status.
8
Treatment quality indicators are
process-based measures which are used
on the assumption that higher perform-
ance scores predict better patient out-
comes.
791 0This has yet to be proven for
indicators of treatment status.
11 12 For
action indicators, positive associations
have been reported between indicators
assessing intensification of glucose-
lowering treatment and glycaemic
control.
61 2 –14 Evidence concerning indi-
cators which assess treatment intensifica-
tion (TI) for other cardiovascular risk
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15 Moreover, little is known
about the sensitivity of treatment indicators to differ-
ences in population characteristics. Quality assessment
may be affected by differences in patient case mix
among providers, but adjusting for these differences is
challenging.
71 61 7
Previously, we investigated the predictive value of
quality indicators of glucose-lowering treatment on
glycaemic control in primary care patients with dia-
betes.
12 In this study, we assess whether quality indica-
tors for treatment of other cardiovascular and renal
risk factors, specifically high cholesterol, blood pres-
sure and albuminuria, predict improvements in short-
term outcomes of patients with type 2 diabetes. In
addition, we assessed to what extent this relationship
is sensitive to differences in patient characteristics.
METHODS
A prospective cohort study was conducted using data
from 2008 to 2009 for patients with diabetes regis-
tered within 150 general practices (GPs) in the prov-
ince of Groningen, The Netherlands. Associations
were assessed between adequate performance accord-
ing to 10 treatment quality indicators as binary inde-
pendent variables and short-term outcomes, adjusting
for baseline values and other confounders at patient
level. Data from all patients with a diagnosis of type 2
diabetes before 1 January 2008 and managed by their
general practitioner were included in this study. GPs
were asked to confirm the documented diagnosis and
date of diagnosis for all patients.
The data were collected from the Groningen Initiative
to Analyse Type 2 Diabetes Treatment (GIANTT) data-
base. This regional longitudinal database includes data
for almost all primary care patients with type 2 diabetes
(<1% opted out) managed by GPs who are contracted
by a regional GP association to get reimbursed for dia-
betes care. In 2008, this association had contracted
around 75% of all GPs in the region, who thereby con-
sented to provide anonymised data related to their dia-
betes care. Routinely registered data are extracted from
electronic medical records (EMRs) using validated pro-
cedures.
18 The data include prescription data,
comorbidity and event data, routine laboratory test
results, and physical examinations. All the GPs prescribe
electronically using the EMR system. In The
Netherlands, each patient is registered with a single GP
who is gatekeeper, and obliged to keep adequate
medical records regarding all relevant diagnostic and
prescription information, including out-of-hours pre-
scriptions made by other practitioners. Prescription data
include information on the drugs’ dosages, daily use
and prescribed quantity, enabling the assessment of
dosage increases and decreases, and switches between
drugs and drug classes. Comorbidity and clinical events
are documented on so-called ‘problem lists’ in the
medical records by means of International Classification
of Primary Care (ICPC) codes
19 or short text descrip-
tions which were manually coded.
In The Netherlands, according to the Code of
Conduct for the use of data in Health Research
(‘Gedragscode gezondheidsonderzoek’ approved in
2004 by the Dutch College for Protection of Personal
Data, taking into account Article 25 of the Dutch Act
on the Protection of Personal Data) no ethics commit-
tee approval was needed for this research using data
from anonymous medical records.
Quality indicators
We selected currently used or recommended quality
indicators for the treatment of cardiovascular and
renal risk factors in patients with diabetes from
national indicator sets
1–3 and previous studies.
41 1
This included three measures of current treatment
(CT) status and seven measures of TI (table 1). We
evaluated the quality of treatment for the year 2008.
The indicators of CT status assess whether patients
with diabetes are treated with lipid-lowering drugs,
patients with elevated blood pressure levels are treated
with blood pressure-lowering drugs, and patients with
elevated albuminuria are treated with albuminuria-
lowering drugs.
1–3 A patient was considered as receiv-
ing treatment when a prescription or refill for drug
treatment was recorded within the last 3 months of
the measurement year,
1 since a single prescription or
refill can be issued for a maximum period of
3 months in The Netherlands.
For indicators of TI, various definitions and thresh-
olds have been used.
11 14 We included thresholds as
recommended in the Dutch guideline, that is, TI is
recommended for patients with levels of low density
lipoprotein cholesterol (LDL-C)>2.5 mmol/litre; sys-
tolic blood pressure (SBP)≥140 mm Hg; and albumin:
creatinine ratio (ACR)≥2.5 mg/mmol (men) and
≥3.5 mg/mmol (women).
20 Since quality of care
might be more at stake at higher thresholds,
72 1we
also included treatment indicators focusing on patients
with more elevated risk factor levels of LDL-C
>3.5 mmol/litre and SBP≥160 mm Hg. Finally, for
blood pressure treatment indicators we included
assessment of whether patients received TI after one
or two elevated blood pressure levels.
We specified TI as starting a new drug class, add-
ition of a new drug class, or dosage increase within
120 days after the initial elevated risk factor test in
2008. This grace period of 120 days was used to
allow for the scenario when providers may give prior-
ity to one condition and postpone the decision regard-
ing another until the next regular visit, which is
conducted every 3 months for patients with diabetes
in The Netherlands.
For lipid-lowering treatment, we included the
classes statins, fibrates, bile acid sequestrants, nicotinic
acid and derivatives, and other lipid-modifying drugs
(omacor, ezitimib, ezetrol). The following five
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lowering treatment: centrally acting antihypertensives,
diuretics, β blockers, calcium channel blockers, drugs
acting on the renin–angiotensin system. For
albuminuria-lowering treatment, we specified intensi-
fication as the start or a dosage increase of an ACE
inhibitor or an angiotensin II receptor blocker (ARB).
The addition of a new drug class was not considered
TI when there was a discontinuation in this or
another class within 7 days, since this indicates a
switch rather than intensification. Furthermore, a
dosage increase was not considered TI when a discon-
tinuation or dosage decrease occurred within 7 days
in this or another class. Patients on maximum treat-
ment were excluded from the intensification indica-
tors, since there is no room for further intensification
of drug treatment in such patients in the primary care
setting. We defined maximum treatment according to
the Dutch guideline for primary care.
20 For
lipid-lowering treatment, the use of one or more
drugs at maximum dosage was considered maximum
treatment. For blood pressure-lowering treatment, the
use of three or more drugs from different classes at
maximum maintenance dosage was considered
maximum treatment. For albuminuria-lowering treat-
ment, prescribing of either an ACE inhibitor or an
ARB at maximum dosage was considered maximum
treatment. Dosage recommendations were obtained
from the Dutch Pharmacotherapy Compendium.
22
Outcomes
Outcomes were the levels of LDL-C, SBP and ACR,
respectively, after the assessed provision of treatment.
For this, we used the first value of LDL-C, the mean
value of all available SBP values and the first value of
ACR within predefined periods (table 1). The time
windows for outcome assessment were based on a
previous study assessing when effects from treatment
can be observed in this population.
23 Thus, we
assessed LDL-C within 21–120 days, SBP within
14–120 days and ACR within 365 days after the last
prescription in 2008 or after the date of TI. The SBP
Table 1 Definition of quality indicators
Quality indicators Baseline factor Definition of quality
Definition of short-term
patient outcome
LDL-C
Patients with diabetes who are treated with
lipid-lowering drugs
First LDL-C test in 2008 Lipid-lowering drug prescription
within last 3 months of 2008
First value of the LDL-C test
in the period 21–120 days
after the prescription date
Patients with diabetes with LDL-C>2.5 mmol/
litre not on maximum treatment receiving
lipid-lowering treatment intensification
First LDL-C test in 2008 if
value>2.5 mmol/litre
Lipid-lowering drug start or
dosage increase within 120 days
after baseline test
First value of the LDL-C test
in the period 21–120 days
after the intensification date
Patients with diabetes with LDL-C>3.5 mmol/
litre not on maximum treatment receiving
lipid-lowering treatment intensification
First LDL-C test in 2008 if
value>3.5 mmol/litre
SBP
Patients with diabetes with SBP≥140 mm Hg
who are treated with blood pressure-lowering
drug(s)
First SBP test in 2008 if
value≥140 mm Hg
Blood pressure-lowering drug
prescription within last 3 months
of 2008
First value of SBP test in the
period 14–120 days after the
drug prescription date
Patients with diabetes with SBP≥140 mm Hg
not on maximum treatment receiving blood
pressure-lowering treatment intensification
First SBP test in 2008 if
value≥140 mm Hg
Blood pressure-lowering drug start
or dosage increase within
120 days after baseline test
First value of SBP test in the
period 14–120 days after the
intensification date
Patients with diabetes with SBP≥160 mm Hg
not on maximum treatment receiving blood
pressure-lowering treatment intensification
First SBP test in 2008 if
value≥160 mm Hg
Patients with diabetes with 2 sequential
SBP≥140 mm Hg receiving blood
pressure-lowering treatment intensification
First SBP test in 2008 with
value≥140 mm Hg
Blood pressure-lowering drug start
or dose increase within 120 days
after baseline test
First value of SBP test in the
period 14–120 days after the
intensification date
Patients with diabetes with 2 sequential
SBP≥160 mm Hg receiving blood
pressure-lowering treatment intensification
First SBP test in 2008 with
value≥160 mm Hg
ACR
Patients with diabetes with ≥2.5 mg/mmol
(men) or ≥3.5 mg/mmol (women) treated
with ACE inhibitors or ARBs
First ACR test in 2008 if
value≥2.5 mg/mmol (men) or
≥3.5 mg/mmol (women)
ACE inhibitor or ARB drug
prescription within last 3 months
of 2008
First value of the ACR test in
the 365-day period after the
prescription date
Patients with ACR≥2.5 mg/mmol (men) or
≥3.5 mg/mmol (women) receiving ACE
inhibitor or ARB treatment intensification
First ACR test in 2008 if
value≥2.5 mg/mmol (men) or
≥3.5 mg/mmol (women)
ACE inhibitor or ARB start or
dosage increase within 120 days
after baseline test
First value of the ACR test in
the 365-day period after the
intensification date
ACE, angiotensin-converting enzyme; ACR, albumin:creatinine ratio; ARB, angiotensin II receptor blocker; LDL-C, low-density lipoprotein cholesterol; SBP,
systolic blood pressure.
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values instead of a single SBP value, because blood
pressure has a high intrapersonal variability. For the
patients who had no treatment or TI, the outcome
was assessed after a randomly generated date which
was computed according to the observed distribution
of treatment prescription dates of patients with treat-
ment or TI. As baseline values we used the initial
values of LDL-C, SBP and ACR in 2008.
Patient characteristics
Patient characteristics associated with the quality indi-
cators can affect the relationship between these indica-
tors and patient outcomes. The following
characteristics were included as possible confounders
and effect modifiers in our study:
17 24 25 general
patient characteristics, that is, age, gender and dur-
ation of diabetes at baseline; comorbidity, including
diabetes-related macrovascular, microvascular and
mental comorbidity. Macrovascular comorbidity
included transient cerebral ischaemia (K89), heart
failure (K77), stroke (K90), atherosclerosis (K91),
myocardial infarction (K75, K76), angina (K74), cor-
onary artery bypass grafting, percutaneous translum-
inal coronary angioplasty and left ventricular
hypertrophy. Microvascular comorbidity included dia-
betes neuropathy (N94.2), retinopathy (F83), renal
failure (U99.1), renal hyperplasia/hydronephrosis
(U99.2,3), terminal dialysis, kidney transplantation,
diabetes foot and related amputations. Mental
comorbidity was identified by any of the ICPC codes
for mental disorders ranging from dementia (P70) to
other mental disorders (P99).
19 Comorbidity was
scored as the presence or absence in the 10 years pre-
ceding 1 January 2008.
Statistical analysis
Using independent t tests, we compared characteristics
of patients receiving treatment according to a quality
indicator with those not receiving the recommended
treatment. We conducted multilevel linear regression
with a random intercept to estimate the impact of the
GP cluster level on the associations between each of
the 10 quality indicators and short-term outcomes.
The proportion of variance that was accounted for by
the GP level was calculated for each model through
intra-class correlation coefficients (ICCs). Since the
ICC was less than 0.01 for all the tested associations,
we present results based on multiple linear regression
analysis that includes the risk factor outcome as a con-
tinuous dependent variable and the provision of treat-
ment or TI (quality indicator) as binary independent
variable at patient level. Patients with missing baseline
or outcome values (loss to follow-up) were excluded
from the analysis per quality indicator. Three models
were built for each indicator to adjust for confound-
ing. The first was the crude model, which only adjusts
for the baseline risk factor level. The second was a
model adjusted for general patient characteristics
(gender, age, duration of disease). The third was a
model also adjusting for different types of comorbidity
(microvascular, macrovascular and mental comorbidity).
We examined confounding and effect modification
of the patient characteristics on the tested associations.
Confounding was investigated by looking at F-ratio
changes and relative changes in estimated effect size
of the associations after adding variables in the model.
Effect modification was examined by testing for
interactions between the quality indicator and other
variables in the fully adjusted models.
We conducted several sensitivity analyses. We first
tested whether using a single blood pressure outcome
instead of the mean value in the outcome period
would change our findings. Second, we checked
whether excluding patients with an outcome value
within the first month after treatment or TI would
change the results. Furthermore, we adjusted the ACR
models also for baseline haemoglobin A1c (HbA1c)
level to take possible confounding of ACR measure-
ment by high HbA1c levels into account. Finally, we
included switching from one drug class to another for
the indicators of lipid and blood pressure lowering TI,
since in some of these cases switches might be made
in reaction to poor risk factor control.
RESULTS
A total of 15 453 patients with diabetes were eligible
for the study (table 2), after excluding 42 patients
who did not have a confirmed date of diagnosis.
Percentages of patients who did not have a baseline
risk factor test in 2008 were 27.4% for LDL-C,
16.1% for SBP and 43.5% for ACR. These patients
received less treatment in comparison to those with
risk factor tests (figure 1, left panel). For uncontrolled
patients, CT rates ranged from 43% to 79% whereas
Table 2 Patient characteristics at baseline
Patient
characteristics
Number of patients with
observation (%) Mean±SD
Age (years) 15453 66.5±12.2
Male gender 7308 (47.5)
Diabetes duration
(years)
15453 2 (4; 8)*
HbA1c (%) 13608 7.0±1.0
LDL-C (mmol/litre) 11212 2.5±0.9
SBP (mm Hg) 12968 143±20.3
ACR (mg/mmol) 8734 4.8±14.2
Macrovascular
comorbidity
2967 (19.2)
Microvascular
comorbidity
777 (5)
Mental comorbidity 784 (5.1)
*Median (25th and 75th percentiles).
ACR, albumin:creatinine ratio; LDL-C, low-density lipoprotein cholesterol;
SBP, systolic blood pressure.
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(figure 1, right panel). The numbers of patients with
available baseline and outcome tests ranged from 539
for the indicator of TI in patients with highly uncon-
trolled LDL-C to 5815 for the indicator of treatments
intensification in patients with uncontrolled SBP
(table 3). The numbers of patients excluded for TI
because of maximum treatment amounted to 5–6% of
patients with elevated LDL levels, <2% of patients
with elevated SBP levels and 23% of patients with ele-
vated ACR levels. The numbers of patients with treat-
ment switches were low, and including switching as TI
did not change any of our findings (see online supple-
mentary appendix A).
Patients receiving TI often had worse related base-
line values in comparison to patients for whom
intensification was indicated but not performed (table
3). There were no large differences in other clinical
characteristics, but patients who received TI were on
average 1–3 years younger than those not receiving
intensification (see online supplementary appendix B).
Quality indicators related to LDL-C
Receiving any lipid-lowering treatment and receiving
intensification of treatment when there was an LDL-C
level>2.5 mmol/litre or >3.5 mmol/litre were signifi-
cantly associated with improvement in LDL-C (table 3).
Adjustment of the association between TI and LDL-C
outcome for comorbidity explained significantly more
variance in the LDL-C outcome (p<0.05), but had a
negligible effect on the effect sizes of the observed asso-
ciations (figure 2). No interactions were seen with base-
line patient characteristics.
Quality indicators related to SBP
Receiving any blood pressure-lowering treatment and
receiving intensification of such treatment when there
was a single elevated SBP were not significantly asso-
ciated with better SBP outcomes. Intensification of
treatment after two SBP tests above 140 mm Hg was
associated with the mean SBP outcome (table 3) but
this association was lost when using a single SBP test or
SBP mean within the period 31–120 days after date of
TI as outcome (see online supplementary appendix A).
The estimated change in SBP was greater when there
was TI after two SBP tests above 160 mm Hg.
Adjustment for patient characteristics explained signifi-
cantly more variance (p<0.01) and changed the pre-
dictive effects of TI after two SBP tests above 140 and
two SBP tests above 160 mm Hg on SBP outcomes
from −1.26 to −0.95 and from −3.81 to
−3.15 mm Hg, respectively (figure 2). No interactions
were seen with baseline patient characteristics.
Quality indicators related to ACR
Receiving albuminuria-lowering treatment was not asso-
ciated with an improvement in ACR but an interaction
with baseline levels was observed. This interaction
showed that in patients with a baseline ACR greater than
30 mg/mmol, receiving albuminuria-lowering treatment
was associated with deterioration in ACR. For instance,
current albuminuria-lowering treatment in a patient with
a baseline ACR of 10 mg/mmol was not associated with
a change in ACR (−2.6 mg/mmol; 95% CI −6.4 to 1.3),
while in patients with a baseline ACR of 40 mg/mmol
CT was associated with a significant deterioration in
ACR (7.1 mg/mmol; 95% CI 2.2 to 12.0). Receiving TI
showed a tendency towards an improvement in ACR
(table 3). Adjustment for patient characteristics explained
significantly more variance in ACR outcome (p<0.01)
and decreased the predictive effect from the TI from
−2.47 to −2.02 mg/mmol (figure 2). Adjusting for base-
line HbA1c values did not change the findings (see
online supplementary appendix A).
Figure 1 Percentage of patients who received current treatment and treatment intensification (TI) among those without a risk factor
test, with well controlled baseline levels and uncontrolled baseline levels (numbers are given below the graphs), excluding patients
already on maximum treatment for TI.
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Our study showed that quality indicators of TI were pre-
dictive of better short-term clinical outcomes in patients
with diabetes. For blood pressure treatment, this was
only the case for intensification in patients with repeat-
edly elevated SBP levels. However, quality indicators
assessing CT status showed only a predictive association
for lipid-lowering drugs. For blood pressure-lowering
treatment and albuminuria-lowering treatment, no asso-
ciations were found with better short-term outcomes.
Adjustment for general patient characteristics and
comorbidity had little effect on the observed associations.
We specifically focused on treatment quality indica-
tors of cardiovascular and renal risk factors in patients
with diabetes. Such indicators are included in several
quality indicator sets and the treatment quality of
these risk factors needs attention. Lower treatment
quality has been observed for patients with diabetes
with elevated blood pressure, cholesterol or ACR
levels than for patients with poor glycaemic
control.
23 26 We included a large unrestricted cohort
of primary care patients with diabetes from the north
of The Netherlands. These patients are relatively well
controlled regarding their HbA1c level, which is con-
sistent with findings from another large Dutch cohort
of patients with diabetes.
27 These patients belong
mostly to the European Continental Ancestry Group
which might influence the response to drug treatment
and thus the strength of the studied associations. For
some indicators, only a limited number of patients
were included, which decreased the power to detect
significant associations. When assessing TI, we
excluded patients already on maximum treatment at
baseline. Inclusion of such patients would classify
them as being not intensified whereas other actions
may have been conducted in these patients which
were not assessed with the quality indicators, thereby
falsely decreasing the associations observed. We
observed differences in baseline risk factor levels and
age of patients with and without CT and TI for
several indicators. Our conclusions are therefore
based on the models adjusting for these factors. Due
Table 3 Numbers of patients with and without the recommended current treatment (CT) and treatment intensification (TI), their mean
baseline and outcome levels, and the effect sizes (with 95% CIs) of the associations between quality indicators and patient outcomes
Label of
indicator
Quality indicators (unit of
baseline and outcome
measure)
Treated
according to
quality indicator
(yes/no)
Number of patients
(with/without
measured
treatment)
Mean
baseline
level
Mean
outcome
level
Estimated change
in risk factor
level‡ (95% CI)
LDL CT Treated with lipid-lowering drugs
(mmol/litre)
Yes 2070 2.4* 2.3† −0.41 (−0.48 to
−0.34) No 365 2.6* 2.8†
TI if
LDL-C>2.5
Treatment intensification in
patients with LDL-C>2.5 (mmol/
litre)
Yes 192 3.9* 2.6† −0.82 (−0.93 to
−0.71) No 1230 3.4* 3.2†
TI if
LDL-C>3.5
Treatment intensification in
patients with LDL-C>3.5 (mmol/
litre)
Yes 117 4.4 2.8† −0.93 (−1.11 to
−0.76) No 422 4.3 3.7†
CT if
SBP≥140
Treated with blood
pressure-lowering drugs in
patients with SBP≥140 (mm Hg)
Yes 4610 157 152 1.25 (−0.81 to
3.32) No 282 157 151
TI if
SBP≥140
Treatment intensification in
patients with SBP≥140 (mm Hg)
Yes 868 165* 153† −0.04 (−1.19 to
1.11) No 4947 154* 148†
TI if
2xSBP≥140
Treatment intensification in
patients with 2 sequential
SBP≥140 (mmHg)
Yes 932 165* 154† −1.26 (−2.28 to
−0.24) No 4698 155* 152†
TI if
SBP≥160
Treatment intensification in
patients with SBP≥160 (mm Hg)
Yes 524 176* 158 −0.58 (−2.20 to
1.13) No 1675 170* 156
TI if
2xSBP≥160
Treatment intensification in
patients with 2 sequential
SBP≥160 (mm Hg)
Yes 580 177* 161 −3.81 (−5.36 to
−2.27) No 1042 171* 163
CT if ACR is
elevated
Treated with ACE inhibitor or ARB
in patients with ACR≥2.5 (men)
or ≥3.5 (women) (mg/mmol)
Yes 1027 16.9 15.8 −0.36 (−4.11 to
3.40) No 120 16.4 15.7
TI if ACR is
elevated
Treatment intensification in
patients with ACR≥2.5 (men) or
≥3.5 (women) (mg/mmol)
Yes 140 15.8 11.8 −2.47 (−5.32 to
0.39) No 964 14.8 13.6
Bold text indicates significant associations (linear regression).
*Significant baseline differences (independent t test).
†Significant outcome differences (independent t test).
‡Estimated changes in risk factor level for the associations not adjusted for patient characteristics and comorbidity.
ACE, angiotensin-converting enzyme; ACR, albumin:creatinine ratio; ARB, angiotensin II receptor blocker; LDL-C, low-density lipoprotein cholesterol; SBP,
systolic blood pressure.
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however, differences in risk factor levels of patients
receiving the recommended care could be larger than
in those not receiving such care. This implies that the
associations for these quality indicators might be over-
estimated. However, we did not have information
about patients’ non-adherence. This may lead to
underestimations of the association between treatment
quality indicators and risk factor levels. The data were
obtained from EMR using validated procedures.
18
Although these records commonly contain all test
results and prescriptions issued in GPs, occasional
Figure 2 Estimated changes (with 95% CIs) in risk factor levels observed per quality indicator, where for each indicator the crude
estimate is presented (●), the one adjusted for general characteristics (▪), and the change adjusted also for comorbidity (▴). The
indicator labels correspond with table 3. ACR, albumin:creatinine ratio; CT, current treatment; LDL-C, low-density lipoprotein
cholesterol; SBP, systolic blood pressure; TI, treatment intensification.
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been missed. Because we included only patients who
were primarily managed by their general practitioner,
this would be uncommon in our study population.
Our study showed that indicators of CT status have
limited predictive value for short-term patient out-
comes. These indicators assess CT in a cross-sectional
manner, that is, whether patients with a specific indi-
cation receive treatment during or at the end of the
measurement period. These indicators are relatively
easy to calculate and are included in several quality
indicator sets.
1–3 For glucose-lowering treatment, it
was found that such an indicator of treatment status
was not associated with better glycaemic control.
12
The predictive value for treatment indicators of other
risk factors, however, was previously not known.
11 In
our study, only lipid-lowering treatment assessed by
means of such a simple treatment indicator was asso-
ciated with better cholesterol outcomes. The absence
of an association between blood pressure-lowering or
albuminuria-lowering treatment status and clinical
outcomes may seem surprising, but is the result of
including patients without further TI and who may
deteriorate. The deterioration in albuminuria observed
among treated patients with highly elevated baseline
albuminuria levels might indicate a more progressive
nature of these advanced cases that are less responsive
to treatment.
Our findings regarding indicators of TI are consist-
ent with previous studies, showing predictive associ-
ation for cholesterol-lowering
14 but not for blood
pressure-lowering TI, when assessed after a single ele-
vated SBP value.
28 Previously, it was also observed
that TI indicators for glucose control predicted better
glycaemic outcomes.
12 What our study adds is that we
also evaluated TI in patients with repeated and highly
elevated risk factor levels, and found that these did
predict improvements in blood pressure and choles-
terol control, respectively. Furthermore, we observed
a trend in predicting better outcomes for intensifying
albuminuria-lowering treatment. Of note is our
finding that patients with and without TI after an ele-
vated blood pressure level improved to similar
outcome values. Thus, the change in blood pressure
and possibly the clinical need appears to be larger for
those receiving TI. This difference in clinical need is
not fully captured when using indicators with cutoff
levels.
Our findings demonstrate that there is a need to
reconsider some of the currently used treatment indi-
cators, as has been proposed by others.
7 Generally,
the value of indicators that look at treatment status in
a cross-sectional manner appeared to be limited. For
assessing the quality of lipid-lowering treatment a
simple treatment indicator may suffice. However,
treatment indicators assessing ‘patients with albumin-
uria treated with ACE-inhibitors’
3 or ‘patients with
elevated blood pressure receiving treatment’ were not
predictive of better short-term patient outcomes.
They could be more indicative of disease severity in
the assessed patient population than of better quality
of care. We have shown that quality assessment using
indicators of TI was more meaningful than the simple
treatment indicators in terms of estimated patient out-
comes. These clinical action indicators are not yet
common for quality assessment since they require
detailed prescription and clinical data and may be dif-
ficult to calculate. The growing use of EMR, however,
presents the opportunity to perform this kind of
assessment in the near future.
7 For blood pressure-
lowering treatment there is an additional requirement,
that is, one should focus on assessing TI in patients
with repeated, not single, elevated levels.
In this study, we only looked at short-term patient out-
comes. Although they are considered as predictors of
morbidity and mortality, testing the direct relationship of
treatment quality indicators to hard outcomes is needed.
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